Sarepta Therapeutics (SRPT) has gained 51% year-to-date, with a closing price of $146.03 on July 29th. Analysts are bullish on SRPT, expecting significant growth driven by the successful launch of Elevidys for Duchenne muscular dystrophy.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing